Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation

Biotech Giants' SG&A Expenses: A Decade of Growth and Strategy

__timestampDynavax Technologies CorporationProtagonist Therapeutics, Inc.
Wednesday, January 1, 2014177630001860000
Thursday, January 1, 2015221800002963000
Friday, January 1, 2016372570006961000
Sunday, January 1, 20172736700011779000
Monday, January 1, 20186477000013697000
Tuesday, January 1, 20197498600015749000
Wednesday, January 1, 20207925600018638000
Friday, January 1, 202110015600027196000
Saturday, January 1, 202213140800031739000
Sunday, January 1, 202315294600033491000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Protagonist Therapeutics, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Dynavax consistently outspent Protagonist, with its SG&A expenses growing by an impressive 760%, reaching a peak in 2023. In contrast, Protagonist's expenses increased by approximately 1,700%, albeit from a much smaller base, highlighting its rapid expansion phase. Notably, Dynavax's expenses surged significantly in 2021, coinciding with its strategic initiatives in vaccine development. Meanwhile, Protagonist's steady rise reflects its ongoing investment in research and development. This financial snapshot underscores the dynamic nature of biotech firms as they navigate growth and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025